A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Public ClinicalTrials.gov record NCT02057133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
Study identification
- NCT ID
- NCT02057133
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 198 participants
Conditions and interventions
Conditions
Interventions
- LY2835219 Drug
- Letrozole Drug
- Anastrozole Drug
- Tamoxifen Drug
- Exemestane Drug
- Everolimus Drug
- Trastuzumab Drug
- LY3023414 Drug
- Fulvestrant Drug
- Pertuzumab Drug
- Loperamide Drug
- Endocrine therapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2014 (Actual)
- Primary completion
- Mar 15, 2021 (Actual)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Jan 26, 2026
2014 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group - Duplicate 2 | Rogers | Arkansas | 72758 | — |
| University of California - San Diego | La Jolla | California | 92037-0845 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic | Rochester | Minnesota | 55905-0002 | — |
| Columbia University College of Phys & Surgeons | New York | New York | 10032 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Providence Cancer Center Oncology Hematology Care | Portland | Oregon | 97213 | — |
| Univ of Pittsburgh Cancer Inst. (UPCI) | Pittsburgh | Pennsylvania | 15213 | — |
| Peggy and Charles Stephenson Oklahoma Cancer Center | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 78229-3307 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02057133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02057133 live on ClinicalTrials.gov.